Postoperative Nausea and Vomiting Clinical Trial
— PONVOfficial title:
The Effect of Oral Honey and Water Up to Two Hours Before Surgery on Postoperative Nausea and Vomiting
Verified date | July 2019 |
Source | Istanbul University-Cerrahpasa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Postoperative nausea and vomiting (PONV) remains current as a complication and moderate
evidence is available regarding the impact of preoperative oral carbohydrate-fluid
administration on PONV. Honey, a natural source of carbohydrates, has an antioxidative effect
and protects the gastric mucosa.
Aim: To investigate the effect of oral honey and water for up to 2 hours preoperatively on
PONV.
Methods: A total of 142 elective thyroidectomy (experiment:35; control:37) and laparoscopic
cholecystectomy (experiment:33; control: 37) patients were included. The experiment group was
administered a 60 grams honey and 100 ml water mixture up to 2 hours preoperatively. The
patients were monitored postoperative 0-6 hours using Rhodes Index of
Nausea-Vomiting-Retching (R-INVR) and visual analog scale (VAS) for PONV.
Status | Completed |
Enrollment | 142 |
Est. completion date | February 19, 2018 |
Est. primary completion date | January 9, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria - Individuals who volunteered to participate in the study - Individuals who have the ability to make decisions - Thyroidectomy operation - Laparoscopic cholecystectomy (Lap. Chol.) operation - Individuals who score 2/5 or more out of the Koivuranta PONV risk factors* Exclusion Criteria - Patients with diabetes, - Nothing by mouth patients (for other reasons than surgery), - Gastrointestinal system surgery patients - Individuals with pollen allergy - Koivuranta PONV risk factors: Female gender, Non-smoking individuals History of PONV History of motion sickness Anesthesia duration |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul University-Cerrahpasa | Istanbul |
Lead Sponsor | Collaborator |
---|---|
OYA GUMUSKAYA BRADLEY |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PONV Occurence in all Participants by Rhodes Index of Nausea, Vomiting and Retching(R-INVR) Scores (8 items; each 0-4 points;total of 0-32 points) | PONV measure; Any score above zero (>0) indicates that participant experienced nausea. Each response is scored as 0: minimum, 4: maximum disturbance, and the score from 8 items was summed. The worst PONV experience can be expressed with the highest value of 32 points. 3 subscales were "experience, occurence, and distress". Experience (total experience score; 32): Nausea Experience Questions: 4,5,7; Total score; 0-12 Vomiting Experience Questions: 1,3,6; Total score; 0-12 Retching Experience Questions: 2,8; Total score; 0-8 Occurence (total occurence score; 20): Nausea Occurence Questions: 4,7; Total score; 0-8 Vomiting Occurence Questions: 1, 6; Total score; 0-8 Retching Occurence Questions: 8; Total score; 0-4 Distress (total occurence score; 12): Nausea Distress Questions: 5; Total score; 0-4 Vomiting Distress Questions: 3; Total score; 0-4 Retching Distress Questions: 2; Total score; 0-4 |
Early postoperative period; 0-6 hours after surgery | |
Primary | The Comparison of PONV Occurence by total R-INVR Scores in the Intervention and Control Groups | PONV measure; Any R-INVR total score above zero (>0) indicates that participant experienced nausea. This results were compared in control and intervention groups. | Early postoperative period; 0-6 hours after surgery | |
Primary | The Comparison of PONV Intensity by Total score of R-INVR (0-32 points) in the Intervention and Control Groups | R-INVR scale total score was summed; higher points indicate worse nausea and/or vomiting Each response is scored between 0 to 4, and the score from 8 items were summed. The worst PONV experience can be expressed with the highest value of 32 points. These scores were compared in control and intervention groups and analysed. | Early postoperative period; 0-6 hours after surgery | |
Primary | The Comparison Between R-INVR Average Scores in the Intervention and Control Groups | R-INVR scale total score was averaged in groups (total score0-32 points by 8 items each 0-4 points) (control, intervention); higher score indicates worse nausea and/or vomiting within the group | Early postoperative period; 0-6 hours after surgery | |
Primary | The Comparison of R-INVR Average Scores by the Intervention and Control groups | R-INVR scale averaged scores were compared in groups (control, intervention); higher score indicates worse nausea and/or vomiting within the group. | Early postoperative period; 0-6 hours after surgery | |
Primary | Visual Analog Scale (VAS) (0-10 points) for PONV | The level of experienced nausea and vomiting described by participants and nurses using VAS; 10 indicates the worst experience of nausea and/or vomiting; and 0, no nausea or vomiting being experienced | Early postoperative period; 0-6 hours after surgery | |
Secondary | Anesthesia duration by minutes (marked as sign in and time out) and PONV occurence (R-INVR total score) comparison | Anesthesia duration (by minutes; defined risk factor) was compared with PONV occurence (measured with total R-INVR score) | Early postoperative period; 0-6 hours after surgery | |
Secondary | The Comparison of Smoking status (smoking or not smoking) of Participants in the Intervention and Control Groups was compared with PONV occurence (R-INVR total score) | People who do not smoke (tobacco) is proved to be under risk for PONV and this status was compared with R-INVR total score. | Early postoperative period; 0-6 hours after surgery | |
Secondary | The Comparison of intraoperative Intravenous Ondansetron and PONV occurence (R-INVR total score >0) in All Participants | Ondansetron use (by patient who received (4 or 8 mg IV during surgery, the dose was determined by anesthesia residents depending on patients' weight, verses patients who did not receive any ondansetron at all during surgery) was analysed against PONV occurence (R-INVR total score>0 or 0) | Early postoperative period; 0-6 hours after surgery | |
Secondary | The Comparison of intraoperative Intravenous Ondansetron and PONV occurence (R-INVR total score >0) in All Participants in the Intervention and Control Groups | Ondansetron use (by patient who received (4 or 8 mg IV during surgery, the dose was determined by anesthesia residents depending on patients' weight, verses patients who did not receive any ondansetron at all during surgery) was compared by PONV occurence (R-INVR total score>0 or 0) in control and intervention groups | Early postoperative period; 0-6 hours after surgery | |
Secondary | The Comparison of the Intensity of PONV Occurence in PONV risk groups (not smoking, women, age <50, over one hour anesthesia, previous experience of PONV or motion sickness) by the total R-INVR scores | The intensity of experienced PONV measured by the total score of R-INVR was analysed according to risk factors (not smoking, women, age <50, over one hour anesthesia, previous experience of PONV or motion sickness) | Early postoperative period; 0-6 hours after surgery | |
Secondary | Gender (men or women) and PONV relation | Woman gender is a described risk factor for PONV and R-INVR results by gender were comprised. | Early postoperative period; 0-6 hours after surgery | |
Secondary | Age and PONV relation | Younger age is a described risk factor for PONV and R-INVR results for PONV were analysed for a relation between R-INVR scores with participants' age. A linear relation was analysed if the R-INVR scores declined by age or not. | Early postoperative period; 0-6 hours after surgery | |
Secondary | Age over and below 50 and PONV relation | The participants' data was divided in two according to age by being over or below 50 years; this was a described risk factor and R-INVR total scores were analysed for a relation between PONV and participants' age. | Early postoperative period; 0-6 hours after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04466046 -
The Effect on Anxiolytics With Type of Antiemetic Agents on Postoperative Nausea and Vomiting in High Risk Patients
|
||
Completed |
NCT03139383 -
Dextrose Containing Fluid and the Postoperative Nausea and Vomiting in the Gynecologic Laparoscopic Surgery
|
N/A | |
Recruiting |
NCT04069806 -
Preoperative Oral Carbohydrate for Nausea and Vomiting Prevention During Cesarian Section
|
N/A | |
Completed |
NCT04043247 -
Transcutaneous Electrical Acupoint Stimulation for Prevention of Postoperative Nausea and Vomiting
|
N/A | |
Terminated |
NCT01975727 -
Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT03662672 -
Rib Raising for Post-operative Ileus
|
N/A | |
Completed |
NCT00090155 -
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT05375721 -
Prevention of PONV With Traditional Chinese Medicine
|
N/A | |
Completed |
NCT02480088 -
Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism
|
Phase 4 | |
Recruiting |
NCT06137027 -
Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting
|
Early Phase 1 | |
Not yet recruiting |
NCT05529004 -
A 6 Months Double Blind Trial to Prevent PONV in Laparoscopic Cholecystectomy
|
Phase 2 | |
Completed |
NCT02944942 -
Risk Factors for Postoperative Nausea/Vomiting
|
N/A | |
Recruiting |
NCT02571153 -
Low Doses of Ketamine and Postoperative Quality of Recovery
|
Phase 4 | |
Completed |
NCT02449291 -
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
|
Phase 3 | |
Completed |
NCT02550795 -
Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer
|
N/A | |
Recruiting |
NCT01442012 -
Utility of Acupuncture in the Treatment of Postoperative Nausea and Vomiting in Ambulatory Surgery
|
N/A | |
Completed |
NCT01478165 -
Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting
|
N/A | |
Unknown status |
NCT01268748 -
Single Port Versus Four Ports Laparoscopic Cholecystectomy and Early Postoperative Pain
|
N/A | |
Completed |
NCT02143531 -
Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting
|
Phase 4 | |
Completed |
NCT00734929 -
Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
|
Phase 4 |